GSK stock gains as UBS stays Neutral and Berenberg turns Buy

Published on 09/17/2026 at 18:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK stock traded at 1,882.00 GBX on September 17, 2026, while UBS kept Neutral. MarketBeat said quarterly EPS was USD 1.36 and revenue USD 11.14 billion.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK plc stock (ISIN GB0009252882) traded at 1,882.00 GBX on September 17, 2026, up 0.88 percent, with a five-day gain of 5.72 percent and a year-to-date rise of 2.88 percent. UBS kept its Neutral view on September 17, 2026, while MarketBeat said the shares changed hands near a USD 101.70 billion market value and a 12-month range of USD 39.29 to USD 61.69.

UBS keeps Neutral

According to MarketScreener on September 17, 2026, UBS kept its Neutral recommendation on GSK and MarketScreener showed a real-time estimate of 1,882.00 GBX, up 0.88 percent on the session. The same page put the five-day move at 5.72 percent and the year-to-date gain at 2.88 percent.

According to MarketBeat on September 17, 2026, GSK reported quarterly EPS of USD 1.36 and revenue of USD 11.14 billion, above analyst estimates of USD 1.27 and USD 11.02 billion. MarketBeat also said revenue rose 5.3 percent year over year and that FY 2026 guidance stands at USD 4.90 to USD 5.00 EPS.

Growth and caution

MarketBeat said GSK's quarterly net margin was 14.56 percent and return on equity 43.23 percent, while the average analyst rating stayed at Hold with a consensus price target of USD 56.50. The same report also noted a quarterly dividend of USD 0.4515, up from USD 0.44 before, and an annualized yield of 3.6 percent.

According to MarketBeat on September 17, 2026, Berenberg upgraded GSK from Hold to Buy, and MarketBeat linked the move to growth outlook and pipeline momentum. It also said GSK agreed to a deal worth up to USD 750 million for an experimental cancer therapy, while MarketBeat described a closure of the Dresden vaccine facility by 2027 as a counter-factor.

Stock level to watch

GSK stock was last quoted at 1,882.00 GBX on September 17, 2026, with the five-day change at 5.72 percent and the year-to-date move at 2.88 percent. The 12-month range on MarketBeat's data was USD 39.29 to USD 61.69 for the ADR, which underlines the gap between the UK quote and the US line.